SCHEMBL9950323

SCHEMBL9950323

[CH]=Cc1csc2ccsc12

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1404098 0.67
SCHEMBL22993641 0.65
SCHEMBL5039590 0.65
SCHEMBL22993523 0.65
SCHEMBL15466884 0.65
SCHEMBL19148888 0.65
SCHEMBL11892127 0.61 GPR35 (0.34) CYP2A6
SCHEMBL23568778 0.60 ALDH1A1 (0.30)
SCHEMBL407079 0.59 GPR35 (0.46) CYP2A6
SCHEMBL23568528 0.58 CA2 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283660-B2 Small molecule semiconductor XEROX CORPORATION (US) 2012-10-09 US disclosed
US-20120161109-A1 SMALL MOLECULE SEMICONDUCTOR XEROX CORPORATION (US) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120161109-A1 SMALL MOLECULE SEMICONDUCTOR SLC43A1, TST, SLC7A5 CYP2A6 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.